TY - JOUR
T1 - Management of hand osteoarthritis
T2 - from an US evidence-based medicine guideline to a European patient-centric approach
AU - Fuggle, Nicholas
AU - Bere, Nathalie
AU - Bruyère, Olivier
AU - Rosa, Mario Manuel
AU - Prieto Yerro, María Concepción
AU - Dennison, Elaine
AU - Dincer, Fitnat
AU - Gabay, Cem
AU - Haugen, Ida K
AU - Herrero-Beaumont, Gabriel
AU - Hiligsmann, Mickaël
AU - Hochberg, Marc C
AU - Laslop, Andrea
AU - Matijevic, Radmila
AU - Maheu, Emmanuel
AU - Migliore, Alberto
AU - Pelletier, Jean-Pierre
AU - Radermecker, Régis Pierre
AU - Rannou, François
AU - Uebelhart, Brigitte
AU - Uebelhart, Daniel
AU - Veronese, Nicola
AU - Vlaskovska, Mila
AU - Rizzoli, René
AU - Mobasheri, Ali
AU - Cooper, Cyrus
AU - Reginster, Jean-Yves
N1 - © 2022. Crown.
PY - 2022/9
Y1 - 2022/9
N2 - Hand osteoarthritis is the most common joint condition and is associated with significant morbidity. It is of paramount importance that patients are thoroughly assessed and examined when complaining of hand stiffness, pain, deformity or disability and that the patient's concerns and expectations are addressed by the healthcare professional. In 2019 the American College of Rheumatology and Arthritis Foundation (ACR/AF) produced guidelines which included recommendations for the treatment of hand osteoarthritis. An ESCEO expert working group (including patients) was convened and composed this paper with the aim to assess whether these guidelines were appropriate for the treatment of hand osteoarthritis therapy in Europe and whether they met with the ESCEO patient-centered approach. Indeed, patients are the key stakeholders in healthcare and eliciting the patient's preference is vital in the context of an individual consultation but also for informing research and policy-making. The patients involved in this working group emphasised the often-neglected area of aesthetic changes in hand osteoarthritis, importance of developing pharmacological therapies which can alleviate pain and disability and the need of the freedom to choose which approach (out of pharmacological, surgical or non-pharmacological) they wished to pursue. Following robust appraisal, it was recommended that the ACR/AF guidelines were suitable for a European context (as described within the body of the manuscript) and it was emphasised that patient preferences are key to the success of individual consultations, future research and future policy-making.
AB - Hand osteoarthritis is the most common joint condition and is associated with significant morbidity. It is of paramount importance that patients are thoroughly assessed and examined when complaining of hand stiffness, pain, deformity or disability and that the patient's concerns and expectations are addressed by the healthcare professional. In 2019 the American College of Rheumatology and Arthritis Foundation (ACR/AF) produced guidelines which included recommendations for the treatment of hand osteoarthritis. An ESCEO expert working group (including patients) was convened and composed this paper with the aim to assess whether these guidelines were appropriate for the treatment of hand osteoarthritis therapy in Europe and whether they met with the ESCEO patient-centered approach. Indeed, patients are the key stakeholders in healthcare and eliciting the patient's preference is vital in the context of an individual consultation but also for informing research and policy-making. The patients involved in this working group emphasised the often-neglected area of aesthetic changes in hand osteoarthritis, importance of developing pharmacological therapies which can alleviate pain and disability and the need of the freedom to choose which approach (out of pharmacological, surgical or non-pharmacological) they wished to pursue. Following robust appraisal, it was recommended that the ACR/AF guidelines were suitable for a European context (as described within the body of the manuscript) and it was emphasised that patient preferences are key to the success of individual consultations, future research and future policy-making.
KW - ADVERSE EVENTS
KW - AMERICAN-COLLEGE
KW - CYCLOOXYGENASE-2 INHIBITORS
KW - DOUBLE-BLIND
KW - GENERAL-POPULATION
KW - HEALTH-CARE
KW - Hand
KW - JOINT OSTEOARTHRITIS
KW - KNEE OSTEOARTHRITIS
KW - Management
KW - NONSTEROIDAL ANTIINFLAMMATORY DRUGS
KW - Osteoarthritis
KW - PLACEBO
KW - Patient-centered
KW - Treatment guideline
U2 - 10.1007/s40520-022-02176-y
DO - 10.1007/s40520-022-02176-y
M3 - (Systematic) Review article
C2 - 35864304
SN - 1594-0667
VL - 34
SP - 1985
EP - 1995
JO - Aging Clinical and Experimental Research
JF - Aging Clinical and Experimental Research
IS - 9
ER -